Skip to main content
. 2015 Feb 15;5(5):515–529. doi: 10.7150/thno.10319

Figure 4.

Figure 4

(A) Selected slice from a 3D gradient echo dataset from MC38 (colorectal) subcutaneous tumour model showing all 4 echoes (echo times shown for each image) acquired post-c(RGDyK)-MPIO administration. (B) Graph showing paired analysis of tumour T2* relaxation times between pre- and post-c(RGDyK)-MPIO treatment in the B16F10 model. (C) Graph showing paired analysis of tumour T2* relaxation times between pre- and post-c(RADyK)-MPIO treatment in the B16F10 model. (D) Graph showing paired analysis of tumour T2* relaxation times between pre- and post-c(RGDyK)-MPIO treatment in the MC-38 model. (E) Graph showing paired analysis of tumour T2* relaxation times between pre- and post-c(RADyK)-MPIO treatment in the MC-38 model. (F,G) Graphs showing percentage reduction in T2* relaxation times following administration of either targeted (c(RGDyK)-MPIO) or control (c(RADyK)-MPIO) contrast agent for B16F10 (F) or MC-38 (G) models. Data are presented as Mean + S.E.M. in bar charts. *P < 0.01, **P < 0.005, ***P < 0.0001.